Understanding how Pseudomonas aeruginosa becomes resistant to cefiderocol.
Official title: Emergence of TonB-dependent receptor mediated cefiderocol resistance among multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates.
Funded at Methodist Hospital Research Institute · NIH-10766821 · Data updated 2026-11-12
This study is looking into how certain tough bacteria, called multidrug-resistant Pseudomonas aeruginosa, become resistant to a new antibiotic called cefiderocol, which could help doctors better treat patients with infections caused by these bacteria.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | January 20, 2023 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $295,785 |
| NIH project number | 5R21AI175821-02 |
| Project ID | NIH-10766821 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research are patients with infections caused by multidrug-resistant Pseudomonas aeruginosa, particularly those in intensive care settings.
✕Less likely to help
Patients with infections caused by non-resistant strains of Pseudomonas aeruginosa may not receive any benefit from this research.
What this research studies
This research investigates the mechanisms behind the resistance of multidrug-resistant Pseudomonas aeruginosa to cefiderocol, a novel antibiotic. By analyzing the genetic changes in clinical isolates, the study aims to identify how these bacteria lose the ability to take up the drug effectively. The approach includes examining the outer membrane proteins responsible for drug transport and assessing the impact of specific mutations on antibiotic efficacy. Patients with infections caused by these resistant strains may benefit from insights gained through this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for infections caused by multidrug-resistant Pseudomonas aeruginosa.
How similar studies have gone: Previous research has shown success in understanding antibiotic resistance mechanisms in other pathogens, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Methodist Hospital Research Institute
Houston, United States Active
Researchers
- Principal investigator: Miller, William R — Methodist Hospital Research Institute
- Study coordinator: Miller, William R
Related research
Other NIH-funded projects on the same topics.
-
Investigating how DNA damage and repair mechanisms are altered in ALS and frontotemporal dementia.
This study is looking at how problems with DNA repair might contribute to conditions like ALS and frontotemporal dementia, and it’s testing ways to fix these issues in cells from patients to help develop new treatments.
-
Cefazolin Inoculum Effect and MSSA Bacteremia: A Rapid Test to Guide Therapy
A study to understand how a high bacterial load affects cefazolin treatment for serious Staphylococcus aureus infections and to test a quick lab method that helps doctors choose the best antibiotic.
-
Cefazolin Inoculum Effect: How this test could improve care for MSSA bloodstream infections
This project tests a quick lab test to find a specific cefazolin resistance pattern in MSSA blood infections so doctors can choose safer, more effective treatment.
-
Vascularized niche with local immune protection to transplant insulin-producing cells for Type 1 diabetes
A new approach aims to transplant insulin-producing cells inside a vascularized pocket with local drug delivery to keep them alive and functioning without full-body immune suppression.
-
How brain connections guide visual choices in ADHD
A research study aims to understand how specific brain pathways help people with ADHD make visual decisions, using non-invasive methods in primates.
-
Why some Klebsiella pneumoniae infections resist key carbapenem antibiotics
This project looks at why certain Klebsiella pneumoniae infections resist carbapenem antibiotics and how those infections affect adult patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.